Ptc Therapeutics (PTCT) Other Accumulated Expenses (2012 - 2026)

Ptc Therapeutics' Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 22.56% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (down 22.56% YoY), while the FY2025 annual figure was $16.5 million, down 20.03% from the prior year.
• Other Accumulated Expenses was $14.6 million for Q1 2026 at Ptc Therapeutics, down from $16.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $28.3 million in Q2 2025 to a low of $1.3 million in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $13.3 million across 5 years, with a median of $12.1 million in 2022.
• Biggest YoY gain for Other Accumulated Expenses was 640.72% in 2022; the steepest drop was 83.2% in 2022.
• A 5-year view of Other Accumulated Expenses shows it stood at $12.1 million in 2022, then dropped by 11.45% to $10.7 million in 2023, then soared by 92.97% to $20.6 million in 2024, then fell by 20.03% to $16.5 million in 2025, then decreased by 11.16% to $14.6 million in 2026.
• The last three Other Accumulated Expenses figures came in at $14.6 million (Q1 2026), $16.5 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.